Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Portola Pharmaceuticals (PTLA) PT Lowered to $30 at Oppenheimer
November 8, 2018 8:29 AM ESTOppenheimer analyst Jay Olson lowered the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $30.00 (from $60.00) while maintaining a Outperform rating.
Olson commented, "PTLA introduced its new CEO and provided a business update in the context of 3Q results. Andexxa revenue at... More
Portola Pharmaceuticals (PTLA) PT Lowered to $30 at Credit Suisse
November 8, 2018 8:10 AM ESTCredit Suisse analyst Vamil Divan lowered the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $30.00 (from $34.00) while maintaining a Neutral rating.
... More